Compare Dishman Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA STRIDES PHARMA SCIENCE DISHMAN PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 25.1 13.8 182.4% View Chart
P/BV x 3.3 0.8 411.8% View Chart
Dividend Yield % 0.7 0.6 111.1%  

Financials

 DISHMAN PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
STRIDES PHARMA SCIENCE
Mar-18
DISHMAN PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3741,147 32.6%   
Low Rs129642 20.1%   
Sales per share (Unadj.) Rs197.8317.2 62.3%  
Earnings per share (Unadj.) Rs21.27.8 270.3%  
Cash flow per share (Unadj.) Rs34.725.1 138.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.2 355.5%  
Book value per share (Unadj.) Rs179.9274.3 65.6%  
Shares outstanding (eoy) m80.6989.50 90.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.8 45.1%   
Avg P/E ratio x11.9114.0 10.4%  
P/CF ratio (eoy) x7.235.7 20.3%  
Price / Book Value ratio x1.43.3 42.9%  
Dividend payout %9.425.5 37.0%   
Avg Mkt Cap Rs m20,30680,058 25.4%   
No. of employees `0000.82.5 33.1%   
Total wages/salary Rs m5,3554,341 123.4%   
Avg. sales/employee Rs Th19,252.711,325.8 170.0%   
Avg. wages/employee Rs Th6,459.51,731.4 373.1%   
Avg. net profit/employee Rs Th2,064.1280.1 737.0%   
INCOME DATA
Net Sales Rs m15,96128,394 56.2%  
Other income Rs m265941 28.2%   
Total revenues Rs m16,22629,334 55.3%   
Gross profit Rs m4,1033,965 103.5%  
Depreciation Rs m1,0911,540 70.8%   
Interest Rs m9441,962 48.1%   
Profit before tax Rs m2,3341,403 166.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-168 -0.7%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m62497 640.9%   
Profit after tax Rs m1,711702 243.7%  
Gross profit margin %25.714.0 184.1%  
Effective tax rate %26.76.9 385.4%   
Net profit margin %10.72.5 433.6%  
BALANCE SHEET DATA
Current assets Rs m11,01824,836 44.4%   
Current liabilities Rs m9,51718,993 50.1%   
Net working cap to sales %9.420.6 45.7%  
Current ratio x1.21.3 88.5%  
Inventory Days Days11071 155.7%  
Debtors Days Days35113 30.7%  
Net fixed assets Rs m16,30434,289 47.5%   
Share capital Rs m161895 18.0%   
"Free" reserves Rs m12,90723,651 54.6%   
Net worth Rs m14,51624,546 59.1%   
Long term debt Rs m4,18915,513 27.0%   
Total assets Rs m29,80565,437 45.5%  
Interest coverage x3.51.7 202.4%   
Debt to equity ratio x0.30.6 45.7%  
Sales to assets ratio x0.50.4 123.4%   
Return on assets %8.94.1 218.8%  
Return on equity %11.82.9 412.1%  
Return on capital %17.56.9 254.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95215,697 31.5%   
Fx outflow Rs m697735 94.8%   
Net fx Rs m4,25514,962 28.4%   
CASH FLOW
From Operations Rs m2,7861,871 148.9%  
From Investments Rs m-1,5295,826 -26.2%  
From Financial Activity Rs m-941-10,157 9.3%  
Net Cashflow Rs m316-2,615 -12.1%  

Share Holding

Indian Promoters % 61.4 27.7 221.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 37.8 9.8%  
FIIs % 12.7 8.6 147.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 25.9 85.3%  
Shareholders   46,261 56,241 82.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PLETHICO PHARMA  AJANTA PHARMA  ALEMBIC LTD  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS